|Bid||6.00 x 0|
|Ask||6.14 x 0|
|Day's Range||5.80 - 6.30|
|52 Week Range||4.62 - 26.85|
|Beta (5Y Monthly)||0.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 23, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.00|
Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new patients to the company's ongoing Phase I clinical trials with the drug candidates ATOR-1015 and ATOR-1017. Patients currently enrolled in clinical studies are expected to continue with their scheduled visits as planned. The company intends to, in consultation with clinical sites and authorities, resume the recruitment of patients as soon as possible.
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed interim CFO, effective 5 March 2020. The recruitment process for a permanent CFO is ongoing. As previously announced, Per-Olof Schrewelius will leave the position as CFO at Alligator.
Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the Swedish version of the Annual Report 2019 is available on the company website www.alligatorbioscience.com. An English version will follow shortly.
Whilst it may not be a huge deal, we thought it was good to see that the Alligator Bioscience AB (publ) (STO:ATORX...
"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project and at year-end, the number had increased to four", commented CEO Per Norlén.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Malin Carlsson as Chief Operating Officer. She most recently comes from a position as Vice President, Head of Translational Medicine at Ferring Pharmaceuticals in Copenhagen.
- Preclinical Data Show that ALG.APV-527 is Well Tolerated with Repeated Dosing - Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response ...
LUND, Sweden, Nov. 6, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinical data showing that their drug candidate ATOR-1017 can induce a long-lasting immunological memory which is of great importance in a potential future patient setting. The results will be presented at the ongoing Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. The ATOR-1017 drug candidate is in development for the treatment of metastasized cancer.
STOCKHOLM , Oct. 24, 2019 /PRNewswire/ -- " We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 substance to, with ...
The nature of investing is that you win some, and you lose some. And there's no doubt that Alligator Bioscience AB...
If you own shares in Alligator Bioscience AB (publ) (STO:ATORX) then it's worth thinking about how it contributes to...